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Understanding the precise molecular mechanisms that trigger liver cancer cell migration and invasion could develop novel therapeutic
strategies targeting cancer cell invasion to increase the sensitivity to current treatment modalities. In the current study, 49 patients
with hepatocellular carcinoma (HCC) were included prospectively. Liver tumour and adjacent non-tumour tissues were detected for
the expression of Proline-rich tyrosine kinase 2 (Pyk2), focal adhesion kinase (FAK), ezrin and fibronectin at protein and/or gene
levels. Correlation between the expressions of Pyk2/FAK with the clinical pathological data was analysed. Protein expression of Pyk2
was also examined in a nude mice orthotopic liver tumour model with higher metastatic potential. There were 59% (29 out of 49)
and 57% (28 out of 49) of HCC patients with higher levels of Pyk2 and FAK protein/gene expression, respectively. We observed a
positive correlation between the protein and gene expression levels of Pyk2 and FAK (P¼0.000, r¼0.875). Overexpression of Pyk2
and FAK was significantly correlated with shorter disease-free survival. Patients with higher levels of Pyk2/FAK had larger tumour size
and advanced Edmonson grading. In the animal studies, Pyk2 overexpression was found in infiltrative tumour cells and lung metastatic
nodules. In conclusion, overexpression of Pyk2 and FAK was found in nearly 60% of HCC patients and was significantly correlated
with poor prognosis. The significance of Pyk2 in HCC invasiveness was confirmed by animal studies.
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Understanding the precise molecular networks that trigger liver
cancer cell migration and invasion could develop novel therapeutic
strategies targeting cancer cell invasion to increase the sensitivity
to current treatment modalities. Focal adhesion kinase (FAK) is an
important mediator of cell proliferation, cell survival and
migration. Recently, clinical evidences demonstrated that FAK
was involved in liver tumour progression and had prognostic
significance for hepatocellular carcinoma (HCC) patients (Fujii
et al, 2004; Itoh et al, 2004). In addition to clinical relevance,
animal experiments also demonstrated that FAK might play
important roles in the regulation of metastatic adhesion of cancer
cells with liver sinusoids and formation of organ-specific distant
metastases. An in vitro study confirmed that FAK integrated
growth-factor and integrin signals to promote cell migration (Sieg
et al, 2000). An in vivo animal model also demonstrated that FAK
is important for lung metastasis in a breast cancer model (van
Nimwegen et al, 2005).
Proline-rich tyrosine kinase 2 (Pyk2), also known as cell
adhesion kinaseb (CAKb), is a tyrosine kinase that is structurally
related to focal adhesion kinase (FAK) (Sasaki et al, 1995). Pyk2
has been demonstrated to be able to promote migration and
invasion of glioma cells (Lipinski et al, 2005) as well as mediate
angiogenesis of pulmonary vascular endothelial cells (Tang et al,
2002). Moreover, Pyk2 also mediated vascular endothelial cadher-
in-based cell–cell adhesion and played an important role in the
modulation of endothelial integrity (van Buul et al, 2005).
However, neither expression study nor functional study of Pyk2
in HCC has been reported. It should be worthwhile to explore the
potential role of Pyk2 in HCC metastases and recurrence.
Recently, FAK became a potentially important new therapeutic
target because of its overexpression in human tumours (McLean
et al, 2005). To study the expression pattern of Pyk2 and its
correlation with clinicopathological data will provide important
information for development of novel therapies targeting at focal
adhesion kinase family including Pyk2. In the current study, we
investigated the correlation between the gene and protein
expression levels of Pyk2 and FAK in liver tumour tissues with
clinicopathological data, and examined the association of potential
metastatic genes (ezrin and fibronectin) with Pyk2. We also
explored the significance of Pyk2 in tumour invasiveness and
metastases in animal models.
MATERIALS AND METHODS
Patients
From December 2000 to October 2001, 49 patients (age over 18
years) diagnosed with HCC that were considered to be resectable
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son the basis of intraoperative ultrasonography without preopera-
tive adjuvant therapy were included in the current study. The new
TNM staging and Edmonson staging of these patients was based on
the clinical and pathological diagnosis (Ng et al, 2006). The study
protocol was approved by the Institutional Review Board of the
University of Hong Kong. Informed consent was obtained from
each patient before operation.
Protein expression of Pyk2 and FAK in tumour and
adjacent non-tumour liver tissues by immunostaining and
Western blot
The paraffin sections of the tissue samples were immunochemi-
cally stained for Pyk2 and FAK using Dako EnVisiont system
(Dako, Glostrup, Denmark). In brief, after de-paraffinisation,
endogenous peroxidase activity was quenched by immersing the
sections for 30min in absolute methanol containing 0.3% H2O2.
The sections were processed to unmask the antigens by conven-
tional microwave oven heating in 10mM citric acid buffer (pH 6.0)
for 12min. The sections were then treated with 10% normal goat
serum for 30min to reduce the background staining, followed by
treatment of appropriate primary antibodies (Pyk2: cytoplasm
staining – H-109, Santa Cruz Biotechnology Inc., 2145 Delaware
Avenue, Santa Cruz, CA, USA; Nuclear staining – Upstate
Biotechnology, Charlottesville, VA, USA; FAK: Upstate Biotechnol-
ogy) at 41C overnight. After washing, the sections were incubated
with EnVisiont secondary antibody for 30min at room tempera-
ture and then visualised with chromogenic substrate solution for
2min. The slides were examined under light microscope by two
independent investigators with the experience of liver pathology.
According to the intensity and area of the staining signalling, the
intracellular protein expression of Pyk2 and FAK was classified
into higher expression (over 50% of tumour section) and lower
expression (less than 50% of tumour section) groups, respectively
by an integrated imaging system (MetaMorph Imaging system
version 3.0; Universal Imaging Corp, West Chester, PA, USA).
Western blot assay was modified from the method described
previously (Liang et al, 2003). Proteins from liver tissues were
prepared by using urea buffer (8 M urea, pH 8.0). Protein extracts
were separated by 12% SDS–PAGE and transferred to PDMF
membrane (Millipore, Billerica, MA, USA) according to the
standard protocol. After blocking with 5% non-fat milk for 1h,
antibody with proper dilution was hybridised with the membrane
at 41C overnight. The membrane was washed three times with tris
buffered saline with tween 20 (TBS/T) each for 10min and
incubated with secondary antibody for 1h at room temperature.
Protein signal was detected by ECL Plus system (Amersham
Biosciences, Piscataway, NJ, USA). The signals were quantified by
scanning densitometry (Syngene, Cambridge, UK).
Gene expression of Pyk2, FAK, ezrin and fibronectin in
tumour tissues by real-time quantitative RT–PCR
Tissue samples were stored at  801C until total RNA extraction.
The total RNA was extracted using Rneasy Midi Kit (Qiagen,
GmbH, Hilden, Germany). About 0.5mg total RNA from each
sample was used to perform reverse transcription (RT) reaction
using TaqMan Reverse Transcription Reagents (Man et al, 2003)
(Applied Biosystems Limited, Foster City, CA, USA). RT product
(1ml) was used to perform real-time quantitative RT–PCR using
TaqMan Core Reagent Kit (Applied Biosystems) by the ABI PRISM
7700 Sequence Detection System (Applied Biosystems) (Man et al,
2003). The probes and primers of Pyk2, FAK, ezrin and fibronectin
were commercially available from Applied Biosystems limited. The
TaqMan Ribosomal RNA Control Reagent (18S RNA probe and
primer pair; Applied Biosystems) was used for internal control in
the same PCR plate well to normalise the target gene amplification
copies. All samples were performed in triplicates. The relative gene
expression levels were calculated as the ratio of the expression of
tumour or non-tumour tissues to normal liver from healthy living
donors.
Functional studies
Reagents and plasmids Plasmids PCDNA3-Pyk2 and PCDNA3-
PRNK (C-terminal of Pyk2) were gifts from Dr Joseph Loftus,
Mayo Clinic Scottsdale, Scottsdale, USA). PCDNA 3.1 (þ) vector
was purchased from Invitrogen. Monoclonal antibody against Pyk2
(clone 11) was purchased from BD Transduction Laboratories.
Polyclonal antibodies against Phospho-Pyk2 (Tyr402) was pur-
chased from Cell Signalling (Beverly, MA, USA). PLC cells were
purchased from ATCC and was grown in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% FBS, 2mML -glutamine,
100unitsml
 1 streptomycin (Life Technologies, Carlsbad, CA,
USA). Metastatic HCC cells MHCC97L was a gift from Dr Tang,
Shanghai Fudan University (Lee et al, 2005).
Cell culture, transfection and stable cell lines Cells were seeded in
six-well plates to 80% confluence. The cells were transfected with
1mgwell
 1 PCDNA 3.1, PCDNA-Pyk2, PCDNA-PRNK plasmids
using Fugene 6 (Roche, Basel, Switzerland). After transfection
overnight, cells were changed to normal medium and allowed to
recover overnight. The cells were trypsinised and seeded into new
10cm culture dish and allowed to recover for 2 days. Cells were
then grown in DMEM containing G418 at 0.6mgml
 1 until all
the non-transfected cells were dead (21 days). Resistant clones
were spread in 24-well plates using cloning cylinders and
maintained in 0.3mgml
 1 G 418 for further study.
Proliferation assay Cells were trypsinised and counted by using a
hemocytometer with 0.2% trypan blue (Life Technologies). Around
5000 cells were seeded onto 96-well plates with DMEM medium
supplemented with 10% FBS, 2mML -glutamine, 100unitsml
 1
streptomycin (Life Technologies). 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) was added at 24h time
interval and signals were measured by a plate reader (BioRad
Hercules, CA, USA).
Cell invasion assay Cells were trypsinised and counted in 0.2%
trypan blue (Life Technologies). Around 10000 cells were counted
and resuspended in 100ml of serum-free DMEM medium. Cells
were seeded on the upper side of the invasion chamber (BD
Biosciences, San Diego, CA, USA). The lower side of the chamber
was filled with DMEM supplemented with 10% fetal bovine serum
and allowed to incubate at 371C for 36h. Cells penetrated through
the chamber were stained with 0.1% crystal violet and counted.
Extraction of nuclear and cytosolic protein Nuclear and cytosolic
proteins were extracted by ProteoExtract
s subcellular proteome
extraction kit (Calbiochem, EMD Biosciences Inc., Merck KGaA,
Darmstadt, Germany) according to manufacturer’s protocol.
Immunoblotting For immunoblotting, fractions were denatured
in sample buffer, and resolved in 8–15% SDS-polyacrylamide gel.
The proteins were transferred to PVDF membrane (Millipore,
Billerica, MA, USA), and immunoblot analysis was performed
using antibodies indicated in figure legends. Immune complexes
on PVDF were detected by enzyme-linked chemiluminescence
(Amersham Biosciences Corp., Piscataway, NJ, USA).
Animal studies
An orthotopic liver tumour model in nude mice with higher
potential of local (intrahepatic) and distant (lung) metastases was
established (Lee et al, 2005). Briefly, approximately 1 10
7
MHCC97H cells in 0.2ml culture medium were injected s.c. into
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sthe right flank of the mice, which were then observed daily for
signs of tumour development. Once the subcutaneous tumour
reached 1–1.5cm in diameter, it was removed and cut into about
1–2mm cubes which were implanted into the left liver lobe of
another group of nude mice. Liver tumour and lung tissues were
harvested for immunostaining of Pyk2 at 5 weeks after tumour
implantation. The liver tumour and lung metastases were
confirmed by H&E staining. The protocol for the in vivo animal
study has been approved by the Committee on the Use of Live
Animals in Teaching and Research (CULATR) of the University of
Hong Kong with meeting the standards required by the UKCCCR
guidelines. The project number is CULATR-1133-05.
Statistical analysis
The w
2 test was used to compare discrete variables. Mann–
Whitney U-test was used for statistical comparison for continuous
variables. Kaplan–Meier method with log–rank test was used for
survival analysis. Po0.05 was considered statistically significant.
Calculation was made using SPSS computer software version 12
(SPSS, Chicago, IL, USA).
RESULTS
Protein and gene expression of Pyk2 and FAK in HCC
patients: distinct expression pattern of Pyk2 and FAK
Different from the previous studies (Stanzione et al, 2001; Lipinski
et al, 2005), positive Pyk2 signals were found both in the cytoplasm
and nuclear of tumour cells of HCC patients (Figure 1A). Focal
adhesion kinase mainly expressed in the cytoplasm of liver cancer
cells (Figure 1B). According to the immunostaining results, there
were 29 (59.2%) patients with higher expression levels of Pyk2 and
28 (57%) patients with higher expression of FAK (Figure 2). The
protein expression by Western blot was consistent with the
immunostaining results (Figure 3). The positive correlation was
found between the protein expression levels of Pyk2 and FAK
(r¼0.875, P¼0.000). The mRNA levels of Pyk2 and FAK detected
by quantitative real time RT–PCR were consistent with the
intracellular protein expression. Significantly higher mRNA levels
of Pyk2 and FAK were found in the tumour tissues of the patients
with higher protein expression of Pyk2 and FAK (Figure 4).
Gene expression of ezrin and fibronectin in HCC patients
with higher or lower protein expression of Pyk2
To examine the correlation of Pyk2 with other potential metastatic
genes, we detected the mRNA levels of ezrin and fibronectin in the
liver tumour and non-tumour tissues. The gene expression levels
of ezrin and firbronectin in liver tumour tissues were found
consistent with their protein expression level of Pyk2 (Figure 4).
Patients with higher protein/gene expression levels of Pyk2 also
had higher mRNA levels of ezrin and fibronectin.
Correlation of the expression of Pyk2 and FAK with
clinicopathological parameters: overexpression of Pyk2
was significantly associated with poor survival and tumour
invasiveness
Patient survival and pathological data were analysed between the
patients with higher or lower protein expression of Pyk2 and FAK
in tumour tissues. The higher intracellular protein expression level
of Pyk2 was significantly correlated with larger tumour size
(P¼0.005), advanced new Edmonson’s staging (P¼0.033) and
venous invasion (P¼0.02) (Table 1). Similar to the results of Pyk2,
overexpression of FAK also contributed to larger tumour size
(P¼0.025) and advanced new Edmonson’s staging (P¼0.017)
(Table 2). However, there was no difference in the incidence of
venous invasion and advanced tumour-node-metastasis staging
between patients with higher and lower expression of FAK.
To further investigate which factors are the potential indepen-
dent predictors of short survival, univariable and multivariable
Cox proportional hazard regression analysis of these factors
corresponding to overall and disease-free survival of the HCC
patients were also performed. Univariable analysis demonstrated
that overexpression of Pyk2/FAK together with other factors were
significantly correlated with overall and disease-free survival of the
HCC patients after curative resection (Tables 3 and 4). However,
multivariable analysis showed that only TNM staging was the
independent factor predicting overall and disease-free survival of
HCC patients (Tables 3 and 4).
Patients with higher protein expression levels of Pyk2 had
significantly lower overall (Figure 5) and disease-free survival
(Figure 6) compared to that of patients with lower expression of
Pyk2. However, patients with higher protein expression levels of
FAK only had lower disease-free survival (Figure 6).
Expression of Pyk2 in HCC cell lines
To study the expression of Pyk2 in HCC cells, Western blot was
performed using monoclonal antibody against Pyk2. Proline-rich
tyrosine kinase 2 was expressed in four of the HCC cells
(Figure 3C). Metastatic cell lines MHCC97L and MHCC97H have
higher expression of Pyk2 as compared to non-metastatic cell lines
PLC and Hep3B.
Distribution of Pyk2 in HCC cells
Previous reports suggest that Pyk2 is localised in the cytoplasm
and perinuclear region. To study the distribution of Pyk2 in
HCC cells, different protein fractions of the cells were collected
and Western blot was performed to study the expression of
Pyk2 (Figure 3D). Pyk2 was distributed in cytoplasm and
membrane fractions. Nuclear distribution of Pyk2 is also observed
in both PLC and MHCC97L cells. The result of this in vitro
subcellular fractionation was consistent with the in vivo
intracellular protein expression pattern of Pyk2 (nuclear and
cytoplasm staining).
A1 A2 B
Figure 1 Intracellular protein expression of Pyk2 (A) and FAK (B). Representative intracellular expression of Pyk2 was found both to be located in the
cytoplasm (A1) nuclear of tumour cells (A2). The positive signals of FAK were found in the cytoplasm of tumour cells (B).
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sPyk2 stimulated proliferation of PLC cells
To characterise further the role of Pyk2 in hepatocellular carcinoma,
MTT assay was carried out to study the proliferation of PLC cells
tranfected with full-length Pyk2 (Figure 6A). Overexpression of Pyk2
in PLC cells caused reproducible increase in cell growth in presence of
10% serum. As compared to vector control, there was a significant
increase in cell proliferation by 25%. Suppression of Pyk2 signalling by
PRNK significantly delayed the proliferation of PLC cells in presence
of serum. There was a 20% decrease in the rate of proliferation of PLC-
A 1a 1b 2a 2b
1c 1d 2c 2d
Tumour Tumour Non-tumour Non-tumour
Tumour Non-tumour
B 1a 1b
2a 2b
Figure 2 Different expression patterns of Pyk2 (A) and FAK (B) by immunostaining. There were 59.2% (29 out of 49) of patients with higher intracellular
expression levels of Pyk2 in tumour tissues (A1-a/c), whereas 40.8% (20 out of 49) of patients had lower intracellular expression levels of Pyk2 (A2-a/c). There
were 57.1% (28 out of 49) of patients with higher intracellular expression levels of FAK in tumour tissues (B1-a), and 42.9% (21 out of 49) of patients hadl o w e r
intracellular expression levels of FAK in tumour tissues (B2-a). Most of the patients had lower levels of expression of Pyk2 and FAK in non-tumour tissues (B2-b).
T
A
B
-Actin
MHCC97L MHCC97H Hep3B PLC
Pyk2
C
1234
PLC MHCC97L
1234
D
Pyk2-y402
Pyk2
NT T NT T NT
T NT T NT T NT
Figure 3 Different protein expression patterns of Pyk2 (A) and FAK (B) by western blot. PYk2 protein expression in different HCC cell lines (C) and
subcellular fractionation of Pyk2 in PLC and MHCC97L cell lines (D) by Western blot. T: tumour; NT non-tumour. 1: cytoplasmic fraction; Fraction 2:
membrane/organelle; Fraction 3: nucleus; Fraction 4: stress fibre.
Pyk2 contributes to HCC growth and invasiveness
CK Sun et al
53
British Journal of Cancer (2007) 97(1), 50–57 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sPRNK cells as compared to vector control. These results suggested that
Pyk2 was involved in the proliferation of PLC cells.
Pyk2 expression promotes Matrigel invasion
In addition to promotion of cancer cell proliferation, Pyk2 also
increased the tumour cell invasiveness detected by the three-
dimensional invasion assays. Pyk2 transfectants had higher ability
to degrade and move through the matrigel (Figure 6B). Normal
PLC cells exhibited the ability to invade the Matrigel. Pyk2
transfectants had 10-fold increased invasion compared to vector
control. These results show that Pyk2 promoted an invasive
phenotype in PLC cells but not in vector control and PRNK
transfectants where the signalling of Pyk2 is being disrupted.
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Figure 4 mRNA expression of Pyk2 (A), FAK (B), Ezrin (C) and fibronectin (D) in tumour and non-tumour tissues by real-time RT-PCR of patients with
higher or lower protein expression of Pyk2 or FAK, respectively.
*: Higher expression vs lower expression: Po0.05.
Table 1 Correlation with clinicopathological parameters–Pyk2
Higher expression
(n¼29)
Lower expression
(n¼20) P-value
Tumour size (cm) 9 (2.5–16) 3.5 (2.3–12) 0.005
New Edmonson
grading (III, IV)
26/29 (89.7%) 12/20 (60%) 0.033
Venous invasion 17/29 (58.6%) 5/20 (25%) 0.02
New TNM
staging (III, IV)
10/29 (34.5%) 3/20 (15%) 0.191
Abbreviations: Pyk2¼proline-rich tyrosine kinase 2; TNM¼tumour-node-metastasis.
Table 2 Correlation with clinicopathological parameters–FAK
Higher expression
(n¼28)
Lower expression
(n¼21) P-value
Tumour size (cm) 8.2 (2.5–16) 3.5 (2.3–15) 0.025
New Edmonson
grading (III, IV)
25/28 (89.2%) 12/21 (57.1%) 0.017
Venous invasion 15/28 (53.6%) 7/21 (33.3%) 0.159
New TNM staging
(III, IV)
9/28 (32.1%) 4/21 (19%) 0.348
Abbreviations: FAK¼focal adhesion kinase; TNM¼tumour-node-metastasis.
Table 3 Cox proportional hazard regression analysis of Pyk2 protein
expression and clinicopathological parameters in relation to the overall
survival of HCC patients
Univariable analysis Multivariable analysis
HR (95% CI) P HR (95% CI) P
Pyk2 protein 4.63 (1.5–14.31) 0.008 3.19 (0.48–21.22) NS
Higher vs lower
expression
FAK protein 3.18 (1.17–8.63) 0.023 2.16 (0.44–10.57) NS
Higher vs lower
expression
New TNM staging 2.09 (1.49–2.93) 0.000 2.42 (1.37–4.23) 0.002
Advanced vs early
staging
Venous invasion 2.97 (1.38–6.41) 0.006 0.4 (0.1–1.64) NS
Presence vs absence
New Edmonson staging 1.08 (0.95–1.23) 0.226 1.23 (0.94–1.63) NS
Advanced vs early
staging
Abbreviations: CI¼confidence interval; FAK¼focal adhesion kinase; HCC¼hepa-
tocellular carcinoma; HR¼hazard ratio; NS¼not significant; Pyk2¼proline-rich
tyrosine kinase 2; TNM¼tumour-node-metastasis.
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sProtein expression of Pyk2 in liver tumour and lung
metastatic nodule in an orthotopic liver tumour model in
nude mice: overexpression of Pyk2 correlated with tumour
invasiveness and metastasis
To further confirm the significance of Pyk2 in HCC invasiveness,
we detected the protein expression of Pyk2 in the liver tumour and
metastatic nodules in an orthotopic liver tumour model in nude
mice. In the orthotopic liver tumour nude mice model with higher
potential of local (intrahepatic) and distant (lung) metastases,
strong positive staining of Pyk2 was found in tumour cells with
infiltrative growth pattern (Figure 7A). The lung metastatic nodule
from the nude mice bearing liver tumour also expressed Pyk2
(Figure 7B). Therefore, the overexpression of Pyk2 was consistent
with the aggressive features of the tumour cells.
DISCUSSION
Development of novel therapies for liver cancer metastases and
recurrence is always essential to achieve the long-term survival
after curative surgical resection (Tung-Ping et al, 2000). Cell
migration and invasion are fundamental components of tumour
recurrence and metastasis. Understanding the precise molecular
mechanism of cancer cell migration and invasion will be important
to develop novel therapeutic strategies targeting tumour metastasis
and recurrence and to increase the sensitivity of current treatment
modalities. Proline-rich tyrosine kinase 2 and FAK play pivotal
roles in the regulation of cell motility and invasion (Sasaki et al,
1995; Sieg et al, 2000; Fujii et al, 2004; Itoh et al, 2004; van
Nimwegen et al, 2005). To explore the role of Pyk2 in liver cancer
invasiveness, it is necessary to investigate the significance of
upregulation of Pyk2 and FAK in tumour recurrence in HCC
patients after curative liver resection, and further study the precise
function of Pyk2 in tumour metastases.
Significant relevance of overexpression of Pyk2 and disease-free
survival was first demonstrated in the current clinical expression
study. Consistent with the poor prognosis, patients with higher
levels of Pyk2 showed aggressive tumour progression, advanced
Table 4 Cox proportional hazard regression analysis of Pyk2 protein
expression and clinicopathological parameters in relation to the disease free
survival of HCC patients
Univariable analysis Multivariable analysis
HR (95% CI) P HR (95% CI) P
Pyk2 protein 5.33 (2.27–14.48) 0.000 2.57 (0.7–9.54) NS
Higher vs lower
expression
FAK protein 3.29 (1.51–7.17) 0.003 2.42 (0.59–9.87) NS
Higher vs lower
expression
New TNM staging 1.61 (1.24–2.93) 0.000 1.87 (1.03–3.36) 0.039
Advanced vs early
staging
Venous invasion 2.68 (1.49–4.82) 0.001 1.35 (0.46–4.02) NS
Presence vs absence
New Edmonson staging 1 (0.89–1.12) 0.975 1.12 (0.77–1.35) NS
Advanced vs early
staging
CI¼confidence interval; HR¼hazard ratio; NS¼not significant.
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Figure 5 Overall survival comparison between patients with higher and lower expression of Pyk2 (A) and FAK (B), respectively. Disease-free survival
comparison between patients with higher and lower expression of Pyk2 (C) and FAK (D), respectively.
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stumour staging and more invasiveness. Positive correlation
between Pyk2 and FAK was also found in our study. In addition
to the detection of Pyk2 and FAK in the liver tumour and non-
tumour tissues, the gene expression levels of ezrin and fibronectin,
two potential metastatic genes, were also investigated according to
patients’ different expression levels of Pyk2. Ezrin, as a key
determinant of tumour metastasis, has been implicated as a
conduit for signals between metastasis-associated cell surface
molecules and signal transduction components (Hunter, 2004;
Khanna et al, 2004). Furthermore, recent study demonstrated the
co-operative effect of ezrin and c-Src, which also correlated with
Pyk2, in cancer cells, in cancer cell metastases (Elliott et al, 2004).
In this study, higher expression levels of ezrin were found to be
consistent with overexpression of Pyk2. Similarly, another gene,
fibronectin, which plays important roles in the promotion of
cancer cell survival, progression and metastasis, presented higher
expression levels in patients with overexpression of Pyk2 (Thant
et al, 2000; Fornaro et al, 2003; Han et al, 2006). The association of
fibronectin and pyk2 has been reported previously (Loeser et al,
2003). The similar expression trend of the genes Pyk2 and FAK
with ezrin and fibronectin might also suggest the potential role of
Pyk2 in liver cancer metastasis/recurrence.
To confirm our findings in clinical samples, we further
conducted in vitro functional studies and an in vivo animal study
in an orthotopic liver tumour model with highly local (intra-
hepatic) and distant (lung) metastatic potential. Our animal study
also first demonstrated that overexpression of Pyk2 was found in
infiltrative liver tumour cells (local metastasis) and lung metastatic
nodules. This in vivo animal study further confirmed the
significant correlation of Pyk2 with HCC invasiveness. In addition
to animal study, our primary function study also indicated that
Pyk2 played important role in HCC cell proliferation and invasion.
However, the distinct cell signalling pathways under the regulation
of Pyk2 related to cell invasion and migration should be
investigated to elucidate the exact molecular mechanism in
addition to the phenomenon demonstrated in our clinical and
animal studies.
In summary, overexpression of Pyk2 and FAK was found in
nearly 60% of HCC patients and was significantly correlated with
poor prognosis. The significance of Pyk2 in HCC invasiveness was
also demonstrated by our orthotopic liver cancer animal model
with higher metastatic potential. Therefore, Pyk2 would be a novel
therapeutic target as well as a prognostic marker in addition to
FAK. Functional studies will be worthwhile for investigation of its
role in liver cancer recurrence and metastases. To examine the
precise molecular mechanism of Pyk2 in liver cancer metastasis
and the possible pathways involved, we are currently conducting a
series of in vitro and in vivo studies. Further studies will be needed
to explore the potential therapies targeting at Pyk2 in liver cancer
recurrence and metastases.
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